Cytotoxicity and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells.
We examined the cytotoxicity, biochemical effects and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine (MRPP), a synthetic nucleoside inhibitor of phosphoribosylpyrophosphate synthetase, in HCT 116 human colorectal cancer cells. A 4-hr exposure to 1 and 10 microM MRPP inhibited cell growth over a 72-hr period by 76 and 89%, and inhibited clonogenic capacity by 36 and 65%, respectively. MRPP was avidly metabolized to the 5'-monophosphate derivative (MRPP-MP), and MRPP-MP formation increased with increasing MRPP exposure (microM.hr). MRPP-MP was stable, and the intracellular half-life was in excess of 48 hr. A 4-hr exposure to 10 microM MRPP resulted in significant decreases in ATP, UTP, GTP, CTP, dATP, dTTP, and PRPP pools. Near maximal ribonucleotide triphosphate depletion was achieved with > or = 24 microM.hr MRPP, and growth inhibition as a function of MRPP microM.hr closely reflected the biochemical effects. Ribonucleotide triphosphate pools remained depleted for up to 48 hr after drug removal, apparently as a consequence of the prolonged retention of MRPP-MP. MRPP (10 microM) inhibited the salvage of [3H]guanine, [3H]adenine and [3H]guanosine, and concurrent exposure to MRPP and either 100 microM adenine, hypoxanthine, or guanine did not reverse ATP or GTP depletion. Concurrent exposure to 10 microM MRPP and either 10 microM adenosine, uridine or thymidine was accompanied by repletion of ATP, UTP, and dTTP pools, respectively, but depletion of other nucleotide pools was not corrected. In contrast, 10 microM guanosine did not correct GTP depletion in the presence of MRPP. The combination of 10 microM each of thymidine, uridine, adenosine and guanosine during and following a 24-hr exposure to MRPP provided partial protection against 0.1 or 1 microM MRPP, but did not affect the cytotoxicity associated with 10 microM MRPP. MRPP is a novel antimetabolite that inhibits both de novo and salvage pathways for purine synthesis and de novo pyrimidine synthesis.
Grem
J L
JL
NCI-Navy Medical Oncology Branch, Bethesda, MD 20889-5105.
Daychild
P
P
Drake
J
J
Geoffroy
F
F
Trepel
J B
JB
Pirnia
F
F
Allegra
C J
CJ
D000255:Adenosine Triphosphate / Q000378:metabolism; D000963:Antimetabolites / Q000378:metabolism / Q000633:toxicity*; D002460:Cell Line; D003570:Cytidine Triphosphate / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis / Q000302:isolation & purification; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009705:Nucleosides / Q000494:pharmacology; D010766:Phosphorylation; D011741:Pyrimidine Nucleosides / Q000378:metabolism / Q000633:toxicity*; D012313:RNA / Q000096:biosynthesis; D014544:Uridine Triphosphate / Q000378:metabolism
D000963:Antimetabolites; D009705:Nucleosides; D011741:Pyrimidine Nucleosides; C061494:4-methoxy-8-(ribofuranosylamino)pyrimido(5,4-d)pyrimidine; D012313:RNA; D003570:Cytidine Triphosphate; D000255:Adenosine Triphosphate; D004247:DNA; D014544:Uridine Triphosphate